AI-powered contentSome parts of this article are powered by AI.
Share this article
Gotrade News - Ocugen (OCGN) granted Celairis Therapeutics an exclusive license to commercialize OCU400, its investigational gene therapy for retinitis pigmentosa, in Australia, New Zealand and ASEAN markets, according to Ocugen's official release on Tuesday, November 10, 2026. Ocugen may receive up to $7.1 million, including the upfront fee.
Regular-session close on November 10, 2026, New York time. Prices and changes: Yahoo Finance, cross-checked against the closing price on Nasdaq.com. Market cap: that close times the shares outstanding on the latest 10-Q or 10-K cover (SEC EDGAR).
What Ocugen Announced
Under the license agreement, Ocugen will receive an upfront license fee and potential development and milestone payments totaling up to $7.1 million, including $6.1 million associated with the upfront payment and OCU400 top-line results, which the company expects in the first quarter of 2027. Ocugen will also receive a high single-digit percentage royalty on net sales and 50% of gross profits from OCU400 net sales in the territory, the release said.
Celairis, a Sydney-based in-licensing, development and commercialization biopharmaceutical company, will be responsible for regional regulatory submissions, market access and commercialization of OCU400. The two companies expect to enter into a supply agreement under which Ocugen will manufacture and supply OCU400. According to the company, the agreement covers a region with an estimated 725 million people.
"This agreement marks our third strategic regional partnership for OCU400," said Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen. Matt Zeller, Chief Executive Officer of Celairis, said Ocugen is "the kind of partner Celairis was built for."
Why It Matters for OCGN
OCU400 has not been approved or registered and is not available for supply in any market of the territory, the release said. Ocugen is conducting the Phase 3 liMeliGhT clinical trial of OCU400, with topline data expected in the first quarter of 2027, followed by planned global regulatory submissions, including a Biologics License Application in the U.S. and a Marketing Authorization Application in Europe. Regulatory submissions in the territory are expected to follow.
Retinitis pigmentosa is a group of inherited retinal diseases that cause progressive vision loss and, in many cases, blindness. Musunuri said partnering with a regional company with a strong local network "is critical to our goal of global patient access," and that the deal underscores "the growing momentum behind our global access strategy."
This article is for education and information only and is not investment advice. Investment decisions are yours to make after your own research.
This article was written with the help of AI and checked by the Gotrade team before publishing.
Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA). This content is for educational purposes only and does not constitute financial advice. Always do your own research (DYOR) before investing.
M. Alfathan Rahman is a content writer with over 3 years of experience developing digital content strategies across various industries, including fintech. He has experience producing content for tax-related websites and financial education platforms. His focus areas include data research, and crafting financial articles that are informative, accurate, and accessible to investors of all experience levels.
